Jason Shoush
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jason Shoush has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Ben Z. Stanger
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
30 shared publications - Benjamin M. Kahn
Department of Medicine, Perelman School of Medicine, University of Pennsylvania (UPenn), Philadelphia, Pennsylvania
30 shared publications - Caius G. Radu
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, USA
30 shared publications - Cynthia Clendenin
University of Pennsylvania Perelman School of Medicine, Abramson Cancer Center, Philadelphia, USA
30 shared publications - Feiyan Mo
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, Texas, USA
30 shared publications - Il-Kyu Kim
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
30 shared publications
Latest Publications
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 selectively inhibits KRASG12D and downstream MAPK signaling in vitro
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 selectively inhibits KRASG12D and downstream MAPK signaling in vitro
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 is selective for KRASG12D in immunocompetent implantation tumor models
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 is selective for KRASG12D in immunocompetent implantation tumor models
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 reduces metastatic burden in a tail vein model
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 reduces metastatic burden in a tail vein model
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Supplementary Figures and Table with legend arranged in a single presentable package
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Supplementary Figures and Table with legend arranged in a single presentable package
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 exerts in vivo effects early in treatment
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 exerts in vivo effects early in treatment
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
KRASG12D inhibition alters the tumor immune microenvironment
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
KRASG12D inhibition alters the tumor immune microenvironment
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 elicits changes in the tumor stroma and vasculature
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 elicits changes in the tumor stroma and vasculature
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Effects of MRTX1133 in KPC/Y and subcutaneous models
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Effects of MRTX1133 in KPC/Y and subcutaneous models
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in implantable and autochthonous PDAC models with an intact immune system. In vitro studies validated the specificity and potency of MRTX1133. In vivo, MRTX1133 prompted deep tumor regressions in all models tested, including complete or near-complete remissions after 14 days. Concomitant with tumor cell apoptosis and proliferative arrest, drug treatment led to marked shifts in the tumor microenvironment (TME), including changes in fibroblasts, matrix, and macrophages. T cells were necessary for MRTX1133's full antitumor effect, and T-cell depletion accelerated tumor regrowth after therapy. These results validate the specificity, potency, and efficacy of MRTX1133 in immunocompetent KRASG12D-mutant PDAC models, providing a rationale for clinical testing and a platform for further investigation of combination therapies.Significance:Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC.See related commentary by Redding and Grabocka, p. 260.This article is highlighted in the In This Issue feature, p. 247
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in implantable and autochthonous PDAC models with an intact immune system. In vitro studies validated the specificity and potency of MRTX1133. In vivo, MRTX1133 prompted deep tumor regressions in all models tested, including complete or near-complete remissions after 14 days. Concomitant with tumor cell apoptosis and proliferative arrest, drug treatment led to marked shifts in the tumor microenvironment (TME), including changes in fibroblasts, matrix, and macrophages. T cells were necessary for MRTX1133's full antitumor effect, and T-cell depletion accelerated tumor regrowth after therapy. These results validate the specificity, potency, and efficacy of MRTX1133 in immunocompetent KRASG12D-mutant PDAC models, providing a rationale for clinical testing and a platform for further investigation of combination therapies.Significance:Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC.See related commentary by Redding and Grabocka, p. 260.This article is highlighted in the In This Issue feature, p. 247